TY - JOUR
T1 - Exome sequencing and unrelated findings in the context of complex disease research
T2 - ethical and clinical implications.
AU - Lyon, Gholson J.
AU - Jiang, Tao
AU - Van Wijk, Richard
AU - Wang, Wei
AU - Bodily, Paul Mark
AU - Xing, Jinchuan
AU - Tian, Lifeng
AU - Robison, Reid J.
AU - Clement, Mark
AU - Lin, Yang
AU - Zhang, Peng
AU - Liu, Ying
AU - Moore, Barry
AU - Glessner, Joseph T.
AU - Elia, Josephine
AU - Reimherr, Fred
AU - van Solinge, Wouter W.
AU - Yandell, Mark
AU - Hakonarson, Hakon
AU - Wang, Jun
AU - Johnson, William Evan
AU - Wei, Zhi
AU - Wang, Kai
PY - 2011/7
Y1 - 2011/7
N2 - Exome sequencing has identified the causes of several Mendelian diseases, although it has rarely been used in a clinical setting to diagnose the genetic cause of an idiopathic disorder in a single patient. We performed exome sequencing on a pedigree with several members affected with attention deficit/hyperactivity disorder (ADHD), in an effort to identify candidate variants predisposing to this complex disease. While we did identify some rare variants that might predispose to ADHD, we have not yet proven the causality for any of them. However, over the course of the study, one subject was discovered to have idiopathic hemolytic anemia (IHA), which was suspected to be genetic in origin. Analysis of this subject's exome readily identified two rare non-synonymous mutations in PKLR gene as the most likely cause of the IHA, although these two mutations had not been documented before in a single individual. We further confirmed the deficiency by functional biochemical testing, consistent with a diagnosis of red blood cell pyruvate kinase deficiency. Our study implies that exome and genome sequencing will certainly reveal additional rare variation causative for even well-studied classical Mendelian diseases, while also revealing variants that might play a role in complex diseases. Furthermore, our study has clinical and ethical implications for exome and genome sequencing in a research setting; how to handle unrelated findings of clinical significance, in the context of originally planned complex disease research, remains a largely uncharted area for clinicians and researchers.
AB - Exome sequencing has identified the causes of several Mendelian diseases, although it has rarely been used in a clinical setting to diagnose the genetic cause of an idiopathic disorder in a single patient. We performed exome sequencing on a pedigree with several members affected with attention deficit/hyperactivity disorder (ADHD), in an effort to identify candidate variants predisposing to this complex disease. While we did identify some rare variants that might predispose to ADHD, we have not yet proven the causality for any of them. However, over the course of the study, one subject was discovered to have idiopathic hemolytic anemia (IHA), which was suspected to be genetic in origin. Analysis of this subject's exome readily identified two rare non-synonymous mutations in PKLR gene as the most likely cause of the IHA, although these two mutations had not been documented before in a single individual. We further confirmed the deficiency by functional biochemical testing, consistent with a diagnosis of red blood cell pyruvate kinase deficiency. Our study implies that exome and genome sequencing will certainly reveal additional rare variation causative for even well-studied classical Mendelian diseases, while also revealing variants that might play a role in complex diseases. Furthermore, our study has clinical and ethical implications for exome and genome sequencing in a research setting; how to handle unrelated findings of clinical significance, in the context of originally planned complex disease research, remains a largely uncharted area for clinicians and researchers.
UR - http://www.scopus.com/inward/record.url?scp=84862833585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862833585&partnerID=8YFLogxK
M3 - Article
C2 - 21794208
AN - SCOPUS:84862833585
SN - 1539-6509
VL - 12
SP - 41
EP - 55
JO - Discovery medicine
JF - Discovery medicine
IS - 62
ER -